NCT05479370View on ClinicalTrials.gov

Immunogenicity Trial of 3 Influenza Vaccines

PHASE3CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

September 29, 2022

Primary Completion Date

April 14, 2023

Study Completion Date

February 6, 2024

Conditions
Influenza Vaccination
Interventions
BIOLOGICAL

Flublok Quadrivalent vaccine

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Fluarix Quadrivalent vaccine

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

Flucelvax Quadrivalent vaccine

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Trial Locations (1)

308442

National Centre for Infectious Diseases (NCID), Singapore

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

A*Star

OTHER

collaborator

University of Melbourne

OTHER

collaborator

Sanofi

INDUSTRY

lead

Tan Tock Seng Hospital

OTHER